

# Sjogren's syndrome - Pipeline Insight, 2021

<https://marketpublishers.com/r/SBA017CB831EEN.html>

Date: July 2021

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: SBA017CB831EEN

## Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Sjogren's syndrome - Pipeline Insight, 2021," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Sjogren's syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Sjogren's syndrome Understanding

#### Sjogren's syndrome: Overview

Sjogren's syndrome is an autoimmune condition that can occur at any age, but is most common in older women. Many patients develop Sjogren's syndrome as a complication of another autoimmune disease, such as rheumatoid arthritis or lupus. Symptoms vary in type and intensity, but many people with Sjogren's are able to live normal lives.

Most of the treatment for Sjogren's syndrome is aimed at relieving symptoms of dry eyes and mouth and preventing and treating long-term complications such as infection and dental disease. Treatments often do not completely eliminate the symptoms of dryness. Most patients with Sjogren's syndrome remain healthy, but some rare complications have been described, including an increased risk for cancer of the lymph

glands (lymphoma). Thus, regular medical care and follow up is important for all patients.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Sjogren's syndrome R&D. The therapies under development are focused on novel approaches for Sjogren's syndrome.

## Sjogren's syndrome Emerging Drugs Chapters

This segment of the Sjogren's syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Sjogren's syndrome Emerging Drugs

### HZN-4920: Horizon Therapeutics

HZN-4920 is a fusion protein binding CD40L on T cells, blocking their interaction with CD40-expressing B cells. It is currently in Phase II stage of development for the treatment of Sjogren's syndrome and is being developed by Horizon Therapeutics.

### Iscalimab: Novartis

Iscalimab is a new, fully human, monoclonal antibody preventing cluster of differentiation 40 (CD40) pathway signaling and activation of CD40+ cell types. It is currently in Phase II stage of development for the treatment of Sjogren's syndrome and is being developed by Novartis.

Further product details are provided in the report.....

## Sjogren's syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Sjogren's syndrome

drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Sjogren's syndrome

There are approx. 20+ key companies which are developing the Sjogren's syndrome. The companies which have their Sjogren's syndrome drug candidates in the most advanced stage, i.e. Phase II include, Horizon Therapeutics.

Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Sjogren's syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sjogren's syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Sjogren's syndrome therapeutic drugs key players involved in developing key drugs.

## Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sjogren's syndrome drugs.

## Sjogren's syndrome Report Insights

Sjogren's syndrome Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## Sjogren's syndrome Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Scenario and Emerging Therapies:

How many companies are developing Sjogren's syndrome drugs?

How many Sjogren's syndrome drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for

Sjogren's syndrome?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sjogren's syndrome therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Sjogren's syndrome and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Horizon Therapeutics

Novartis

Galapagos

Sanofi

Resolve Therapeutics

Bristol-Myers Squibb

Cytodyn

MeiraGTx

Alpine Immune Sciences

Servier

## Key Products

HZN-4920

Iscalimab

LOU-064

GLPG3970

SAR441344

RSLV-132

BMS-986325

AAV-AQP1

ALPN-303

S95011

## Contents

- Introduction
- Executive Summary
- Sjogren's syndrome: Overview
  - Structure
  - Mechanism of Action
- Pipeline Therapeutics
  - Comparative Analysis
- Therapeutic Assessment
  - Assessment by Product Type
  - Assessment by Stage and Product Type
  - Assessment by Route of Administration
  - Assessment by Stage and Route of Administration
  - Assessment by Molecule Type
  - Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
  - Comparative Analysis
- Drug Name: Company Name
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
  - Comparative Analysis
- HZN-4920: Horizon Therapeutics
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
  - Comparative Analysis
- BMS-986325: Bristol-Myers Squibb
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Preclinical Stage Products
  - Comparative Analysis



AAV-AQP1: MeiraGTx

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Sjogren's syndrome Key Companies

Sjogren's syndrome Key Products

Sjogren's syndrome- Unmet Needs

Sjogren's syndrome- Market Drivers and Barriers

Sjogren's syndrome- Future Perspectives and Conclusion

Sjogren's syndrome Analyst Views

Sjogren's syndrome Key Companies

Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Sjogren's syndrome

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Sjogren's syndrome
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Sjogren's syndrome - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/SBA017CB831EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SBA017CB831EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970